Preclinical Data on Combretastatin A4 Phosphate Released

August 7, 2007

Oxigene announced the publication of data from a preclinical study of two triple-drug combinations for the treatment of tumors.

One combination is combretastatin A4 phosphate (CA4P), paclitaxel and manumycin A, while the other is CA4P, paclitaxel and carboplatin.

According to Oxigene, both triple-drug combinations indicated positive antineoplastic activity in mouse xenograft models of anaplastic thyroid cancer (ATC) utilizing two human ATC cell lines.

A paper published August 6 in the Journal of Clinical Endocrinology and Metabolism, reported that both triple-drug combinations incorporating CA4P showed positive results, as determined by tumor volume and weight assessments, in mouse xenograft models of ATC utilizing two human ATC cell lines, the company said.

In addition, correlative studies undertaken by the authors corroborated vascular disruption/tumor blood-flow shutdown as the primary mechanism by which CA4P exerted its antitumor activity in these models, the company added.